Helicobacter Pylori Infection
395
35
42
195
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Published Results
27 trials with published results (7%)
Research Maturity
195 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
1.5%
6 terminated out of 395 trials
97.0%
+10.5% vs benchmark
45%
179 trials in Phase 3/4
14%
27 of 195 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 195 completed trials
Clinical Trials (395)
White Light Endoscopy and Magnifying Endoscopy in Assessing the Status of Hp Infection
Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment
Pylori Duo for Adjunctive Treatment and Prevention of Recurrence of Helicobacter Pylori Infection
Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection
Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion
Effect of PPIs on Stool DNA Test for H. Pylori
Vonoprazan High-Dose Dual VS Levofloxacin Concomitant
Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication
New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool
Tegoprazan-containing Sequential for H. Pylori
Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
Optimization of Minocycline for Helicobacter Pylori Rescue Treatment
Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity
Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound
Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study
Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
H. Pylori Eradication With Argon Plasma During Endoscopy
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication